JW Therapeutics

JW Therapeutics (HKEX: 2126) is an independent, innovative biotechnology company focused on the research and development, manufacturing, and commercialization of cellular immunotherapy products. Guided by innovation, the company strives to become a leader in cellular immunotherapy. Founded in 2016, JW Therapeutics has successfully established an internationally leading, comprehensive product development platform for cellular immunotherapy, along with a pipeline of cellular immunotherapy products covering hematologic malignancies, solid tumors, and autoimmune diseases. Committed to delivering breakthrough, high-quality cellular immunotherapy products, JW Therapeutics aims to bring hope for cure to patients in China and worldwide, while spearheading the healthy and standardized development of China’s cellular immunotherapy industry.